original article

Predictors of Noninvasive Ventilation Failure in Intensive Care Unit

Ahmed G. EL-Gazzar^a, Amany A. Abd Allah^b, Mohamed S. Ali^a, Rehab E. El-Sawy^a

^a Chest Diseases Department, Faculty of Medicine Benha University, Egypt.

BENH

^b Critical Care Department, Faculty of Medicine Benha University, Egypt.

Corresponding to: Mohamed S. Ali, Chest Diseases Department, Faculty of Medicine Benha University, Egypt.

Email: Shabanmoh8@gmail.com

Received: 27 July 2024

Accepted: 9 March 2025

Abstract:

Background: : Non-invasive ventilation (NIV) has emerged as a preferred alternative to invasive mechanical ventilation, offering benefits such as reduced intensive care unit, respiratory center unit stay, lower complication rates, and improved patient outcomes. However, NIV failure remains a critical concern. Aim of Work: Identification of the predictors of noninvasive ventilation failure among patients admitted in RCU in Benha University hospital. Methods: This prospective observational study was conducted to 100 Patients presented with Acute Renal Failure (ARF) and was admitted to Respiratory Critical Unit (RCU), Chest Department in Benha University Hospitals from June 2022 to June 2023. Patients were divided into two groups: successful NIV (n=63) and failed NIV (n=37). Results: Significant predictors of NIV failure included higher heart rate, systolic blood pressure, and respiratory rate, along with lower diastolic blood pressure (P < 0.001). Conditions such as chronic obstructive pulmonary disease and pneumonia were more common in the failed NIV group (P < 0.001), while pulmonary oedema was more prevalent in the successful NIV group (P < 0.05). Cardiac and renal comorbidities were significantly associated with successful NIV. PaCO2 levels, acute physiology and chronic health evaluation scores were higher in the failed NIV group. Multivariate regression identified weight, body mass index, cardiac and renal comorbidity, acute admissions, APACHE score, and sex,

weight, BMI, cardiac and renal comorbidity, acute admission, types of lung disease, were independent predictors of failed NIV (P <0.05) while sex was not. **Conclusion:** Weight, BMI, cardiac, renal comorbidity, acute admission, APACHE and BiPAP were independent predictors of NIV failure in RCU patients.

Keywords: Noninvasive Ventilation Failure, Acute Respiratory Failure, Respiratory Center Unit stay.

Introduction

Acute respiratory failure (ARF) has a steady increase in the number of ICU hospitalization at an average annual rate of 11.8% in 2015 to 2021 with a decrease in inpatient mortality in the United States^[1].

ARF characterized by the impaired respiratory system to exchange gases and to oxygenate the blood, resulting in hypoxia with or without hypercapnia. Two main mechanisms of ARF include failure in pulmonary ventilation caused by neuromuscular diseases. chest wall deformities. obstructive pulmonary diseases, and failure in gas exchanges caused by adult acute respiratory distress syndrome, acute cardiogenic pulmonary oedema, pneumonia, airspace collapse (atelectasis) and pulmonary embolism^[2].

Non-invasive ventilation (NIV) refers to the delivery of mechanical ventilation without using an invasive artificial airway (endotracheal tube or tracheostomy tube) that markedly increases over the past two decades worldwide among patients admitted in RCU^[3].

NIV has become an alternative to invasive mechanical ventilation for the management of ARF, since it can decrease the length of stay in the RCU, reduce the number of possible complications, increase the quality of life, reduce risk of infection and improve the chance of survival, compared to conventional invasive ventilation ^[4].

The effectiveness of NIV varies according to the etiology of respiratory failure NIV for ARF should be performed in a clinical environment with adequate nurse-topatient ratios and monitoring. The choice of facility level should be selected according to disease severity and the coexistence of other organ failure ^[5].

NIV failure has been defined as the need for endotracheal intubation (ETI) or death. Its rate greatly varies between 5 and 60%, depending on numerous factors, including the cause of ARF. Unsuccessful NIV was found to be independently associated with death, especially in patients with de novo ARF^[4].

The aim of this work: Identification of the predictors of non-invasive ventilation failure among patients admitted in RCU in Benha University hospital.

Patients and Methods:

This prospective observational study was conducted to 100 Patients presented with (ARF) and was admitted to the (RCU), Chest Department in Benha University Hospitals during the period between June 2022 to June 2023 after the approval of the Institutional Ethical Committee with **approval code (Ms 37-10-2022).**

There are adequate provisions to maintain privacy of participants and confidentiality of the data.

Inclusion Criteria:

Patients from 20 to 60 years old, with ARF due to difficult etiology resulting from all kinds of diseases such as pneumonia, acute respiratory distress syndrome (ARDS),Chronic obstructive pulmonary disease (COPD), asthma, and cardiogenic pulmonary edema, and Eligible for Non-Invasive ventilation were included in the study

Exclusion Criteria:

While patients with disturbed conscious level, excessive secretion, vomiting or uncooperative, females who were pregnant or with facial deformity and facial surgery and major causes requiring RCU admission were excluded Eligible for non – invasive ventilation NIV.

Methods:

All patients were subjected to history taking(Age, sex, Body mass index (BMI), Weight, previous hospital admission, previous Intensive Care Unit admission, need previous of NIV and other comorbidities), complete clinical examination included (Blood was Pressure, Heart rate, Respiratory rate, Temperature, Diastolic blood pressure, Systolic blood pressure, Conscious level by Glasgow Coma Scale). local examination (Clinical Evaluation by The Sequential Organ Failure Assessment (SOFA)), Routine laboratory investigation (CBC, liver functions test, kidney functions test, random blood sugar, arterial blood gas and serum electrolytes), radiological investigations (Chest X-Ray, CT-Chest, ECHO).

Statistical analysis

This prospective observational study was conducted on 100 patients presented with ARF and were admitted to ICU Benha University Hospitals and divided into two groups

Statistical analysis was done by SPSS v26 (IBM Inc., ARMONK, IL, USA). Shapiro-Wilks test and histograms were used to evaluate the normality of the distribution of data. Quantitative parametric variables were presented as mean and standard deviation (SD) and compared between the two groups utilizing unpaired Student's ttest. Quantitative non-parametric data were presented as median and interquartile range (IQR) and were analyzed by Mann Whitney-test. Qualitative variables were presented as frequency and percentage (%) and were analyzed utilizing the Chi-square test or Fisher's exact test when appropriate. Univariate regression was used to estimate the relationship between а dependent variable and one independent variable. Multivariate regression was also used to estimate the relationship between a dependent variable and more independent variables. A two tailed P value < 0.05 was considered statistically significant.

Results:

Weight and BMI were significantly higher in the Successful NIV group compared to the Failed NIV group (P < 0.001). Heart rate, systolic blood pressure, and respiratory rate were significantly lower, while diastolic blood pressure was higher in the Successful NIV group (P < 0.001). COPD and pneumonia were less prevalent in the Successful NIV group (P < 0.001), whereas pulmonary oedema and cardiac issues were more common (P < 0.05 and P= 0.004, respectively). Renal issues and acute admissions were also higher in the Successful NIV group (P = 0.009 and <0.001). Leukocytes were significantly lower in the Successful NIV group (P <0.001), while kidney functions (creatinine and urea) and serum potassium were better in the Successful NIV group (P < 0.001). Other variables, including liver functions and serum Na, Mg, Ca, and haematocrit, showed no significant differences between the groups. Table 1

pH and HCO_3 were insignificantly different at admission, 6h, 12h, 24h and 48h between both groups. PaCO₂ was significantly higher at admission, 6h, 12h, 24h and 48h in Failed NIV than Successful NIV (P value<0.001). **Table 2**

APACHE score was significantly lower in successful NIV compared to failed NIV (P<0.001). NIV (BiPAP) was significantly higher in successful NIV group than failed NIV (P<0.001). **Table 3**

In univariate and multivariate regression, sex, weight, BMI, cardiac and renal comorbidity, acute admission, types of lung disease, APACHE and BiPAP, weight, BMI, cardiac and renal comorbidity, recurrent or acute admission, types of lung disease, APACHE and BiPAP were independent predictors of failed NIV (P < 0.05) while sex wasn't. **Table 4**

$\begin{array}{c c c c c c c c c c c c c c c c c c c $			Successful NIV(n=63)	Failed NIV (n=37)	Р
Sex Female 35(55.56%) 10(27.03%) 0.000* Weight (kg) 80.1±14.08 70.11±10.9 <0.001*	Age (years)		42.71±10.51	43.08±10.49	0.866
Female $35(55.56\%)$ $10(27.05\%)$ Weight (kg) 80.1 ± 14.08 70.1 ± 10.9 $<0.001^\circ$ Height (m) 1.65 ± 0.08 1.66 ± 0.07 0.767 BMI (kg/m ²) 30.67 ± 5.43 25.6 ± 4.35 $<0.001^\circ$ DBP (mstlg) 76.89 ± 8.14 49.62 ± 3.01 $<0.001^\circ$ DBP (mmHg) 76.89 ± 8.14 49.62 ± 3.01 $<0.001^\circ$ Respiratory rate (breaths/min) 18.92 ± 3.42 41.51 ± 3.36 $<0.001^\circ$ COPD $9(14.29\%)$ $31(83.78\%)$ $<0.001^\circ$ Pulmonary edema $42(66.67\%)$ $7(18.92\%)$ $<0.001^\circ$ Pneumonia $21(33.33\%)$ $30(81.08\%)$ $<0.001^\circ$ Obstructive Sleep Apnea $30(47.6\%)$ $7(18.92\%)$ 0.005^* DM $23(36.51\%)$ $10(26.32\%)$ 0.383 Geororbidity Hypothyroidism $1(1.59\%)$ $2(5.41\%)$ 0.004^* actice $9(30.16\%)$ $2(5.41\%)$ 0.004^* actice $19(30.16\%)$ $2(5.41\%)$ 0.004^*	Sov		· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·	0 006*
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		Female	· · · · · · · · · · · · · · · · · · ·	. , ,	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $					<0.001*
$\begin{array}{c c c c c c c c c c c c c c c c c c c $					
$\begin{array}{c c c c c c c c c c c c c c c c c c c $					<0.001*
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	HR (beats/min	l)	80.75±10.02	106.27 ± 11.15	<0.001*
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	DBP (mmHg)		76.89±8.14	49.62 ± 3.01	<0.001*
COPD 9(14.29%) 31(83.78%) <0.001 ⁴ Pulmonary edema 42(66.67%) 7(18.92%) <0.001 ⁴ Pneumonia 21(33.33%) 30(81.08%) <0.001 ⁴ Obstructive Sleep Apnea 30 (47.6%) 7 (18.92%) 0.005 [*] DM 23(36.51%) 10(26.32%) 0.383 HTN 8(12.7%) 7(18.42%) 0.402 Associated DM and HTN 12(19.05%) 6(16.22%) 0.793 comorbidity Hypothyroidism 1(1.59%) 2(5.41%) 0.553 Cardiac 19(30.16%) 2(5.41%) 0.004* Renal 6(9.52%) 11(29.73%) 0.009* Recurrent or RA 48(76.19%) 14(37.84%) acute admission Laboratory Parameters CBC Hematocrit (%) 40.92±9.64 42.11±0.11 0.560 Leukocytes (x 10 ⁹ /L) 8.78±2.51 17.55±4.21 <0.001 ⁴ test ALT (U/L) 51.97±17.24 50.68±17.32 0.719 test ALT (U/L) 52.57±	SBP (mmHg)		127.03±12.76	155.14±9.15	<0.001*
Pulmonary edema 42(66.67%) 7(18.92%) <0.001 ⁺ Pneumonia 21(33.33%) 30(81.08%) <0.001 ⁺ Obstructive Sleep Apnea 30 (47.6%) 7 (18.92%) 0.005 [*] DM 23(36.51%) 10(26.32%) 0.383 HTN 8(12.7%) 7(18.42%) 0.402 Associated DM and HTN 12(19.05%) 6(16.22%) 0.793 comorbidity Hypothyroidism 1(1.59%) 2(5.41%) 0.553 Cardiac 19(30.16%) 2(5.41%) 0.004* Recurrent or RA 48(76.19%) 14(37.84%) acute admission AA 15(23.81%) 23(62.16%) <0.001 ⁺ Leukocytes (x 10 ⁹ /L) 8.78±2.51 17.55±4.21 <0.001 ⁺ test ALT (U/L) 52.57±24.18 59.86±26.5 0.163 Albumin (mg/dl) 0.33±0.1 0.35±0.1 0.2840 Kidney Creatinine (mg/dl) 3.1 ± 0.98 6.06±1.76 <0.001	Respiratory ra	ate (breaths/min)	18.92 ± 3.42	41.51±3.36	<0.001*
Pneumonia 21(33.33%) 30(81.08%) <0.0015 Obstructive Sleep Apnea 30 (47.6%) 7 (18.92%) 0.005* DM 23(36.51%) 10(26.32%) 0.383 HTN 8(12.7%) 7(18.42%) 0.402 Associated DM and HTN 12(19.05%) 6(16.22%) 0.793 comorbidity Hypothyroidism 1(1.59%) 2(5.41%) 0.553 Cardiac 19(30.16%) 2(5.41%) 0.009* Recurrent or RA 48(76.19%) 14(37.84%) 40.009* acute admission AA 15(23.81%) 23(62.16%) <0.001*	COPD		9(14.29%)	31(83.78%)	<0.001*
Pneumonia 21(33.33%) 30(81.08%) <0.0015 Obstructive Sleep Apnea 30 (47.6%) 7 (18.92%) 0.005* DM 23(36.51%) 10(26.32%) 0.383 HTN 8(12.7%) 7(18.42%) 0.402 Associated DM and HTN 12(19.05%) 6(16.22%) 0.793 comorbidity Hypothyroidism 1(1.59%) 2(5.41%) 0.553 Cardiac 19(30.16%) 2(5.41%) 0.009* Recurrent or RA 48(76.19%) 14(37.84%) 40.009* acute admission AA 15(23.81%) 23(62.16%) <0.001*	Pulmonary eden	ma	42(66.67%)	7(18.92%)	<0.001*
DM 23(36.51%) 10(26.32%) 0.383 HTN 8(12.7%) 7(18.42%) 0.402 Associated DM and HTN 12(19.05%) 6(16.22%) 0.793 comorbidity Hypothyroidism 1(1.59%) 2(5.41%) 0.004* Renal 6(9.52%) 11(29.73%) 0.009* acute admission AA 48(76.19%) 14(37.84%) Laboratory Parameters CBC Hematocrit (%) 40.92±9.64 42.11±0.11 0.560 Leukocytes (x 10°/L) 8.78±2.51 17.55±4.21 <0001* Liver function AST (U/L) 51.97±17.24 50.68±17.32 0.719 test ALT (U/L) 52.57±24.18 59.86±26.5 0.163 Albumin (mg/dl) 0.33±0.1 0.35±0.1 0.286 Kidney Creatinine (mg/dl) 3.1 ± 0.98 6.06±1.76 <0.001 function test Urea (mg/dl) 136.03±5.85 136.65±5.99 0.615 Serum Na(mEq/L) 136.03±5.85 136.65±5.99 0.615 Serum Mg(mg/dL)	Pneumonia		21(33.33%)	30(81.08%)	<0.001*
HTN 8(12.7%) 7(18.42%) 0.402 Associated comorbidity DM and HTN 12(19.05%) 6(16.22%) 0.793 Hypothyroidism 1(1.59%) 2(5.41%) 0.553 0.004* Renal 6(9.52%) 11(29.73%) 0.009* Recurrent or acute admission RA 48(76.19%) 14(37.84%) 0.001* Laboratory Parameters CBC Hematocrit (%) 40.92±9.64 42.11±0.11 0.560 Leukocytes (x 10°/L) 8.78±2.51 17.55±4.21 0.001* Liver function AST (U/L) 51.97±17.24 50.68±17.32 0.719 test ALT (U/L) 52.57±24.18 59.86±26.5 0.163 Albumin (mg/dl) 0.33±0.1 0.35±0.1 0.286 Kidney Creatinine (mg/dl) 3.1 ± 0.98 6.06±1.76 <0.001 function test Urea (mg/dl) 136.03±5.85 136.65±5.99 0.615 Serum Na(mEq/L) 136.03±5.85 136.65±5.99 0.615 Serum Mg(mg/dL) 2.23±0.36 2.28±0.41 0.508 <td>Obstructive Sle</td> <td>ep Apnea</td> <td>30 (47.6%)</td> <td>7 (18.92%)</td> <td>0.005*</td>	Obstructive Sle	ep Apnea	30 (47.6%)	7 (18.92%)	0.005*
Associated comorbidity DM and HTN 12(19.05%) 6(16.22%) 0.793 comorbidity Hypothyroidism 1(1.59%) 2(5.41%) 0.553 Cardiac 19(30.16%) 2(5.41%) 0.004* Renal 6(9.52%) 11(29.73%) 0.009* Recurrent or acute admission RA 48(76.19%) 14(37.84%) CBC Hematocrit (%) 40.92±9.64 42.11±0.11 0.560 Leukocytes (x 10°/L) 8.78±2.51 17.55±4.21 <0.001*		DM	23(36.51%)	10(26.32%)	0.383
comorbidity Hypothyroidism 1(1.59%) 2(5.41%) 0.553 Cardiac 19(30.16%) 2(5.41%) 0.004* Renal 6(9.52%) 11(29.73%) 0.009* Recurrent or admission RA 48(76.19%) 14(37.84%) AA 15(23.81%) 23(62.16%) CBC Hematocrit (%) 40.92±9.64 42.11±0.11 0.560 Leukocytes (x 10°/L) 8.78±2.51 17.55±4.21 <0.001* Liver function test ALT (U/L) 51.97±17.24 50.68±17.32 0.719 Bilirubin (mg/dl) 28.54±7.34 28.59±6.92 0.971 Bilirubin (mg/dl) 0.33±0.1 0.35±0.1 0.286 Kidney Creatinine (mg/dl) 3.1 ± 0.98 6.06±1.76 <0.001 function test Urea (mg/dl) 149.97±18.16 183.7±19.7 <0.001 Serum Na(mEq/L) 136.03±5.85 136.65±5.99 0.615 Serum Ma(mEq/L) 4.02±0.48 2.33±0.28 <0.001		HTN	8(12.7%)	7(18.42%)	0.402
Cardiac 19(30.16%) 2(5.41%) 0.004* Renal 6(9.52%) 11(29.73%) 0.009* Recurrent or RA 48(76.19%) 14(37.84%) acute admission AA 15(23.81%) 23(62.16%) Laboratory Parameters CBC Hematocrit (%) 40.92±9.64 42.11±0.11 0.560 Leukocytes (x 10 ⁹ /L) 8.78±2.51 17.55±4.21 <0.001	Associated	DM and HTN	12(19.05%)	6(16.22%)	0.793
Renal 6(9.52%) 11(29.73%) 0.009* Recurrent or acute admission RA 48(76.19%) 14(37.84%) AA 15(23.81%) 23(62.16%) Laboratory Parameters CBC Hematocrit (%) 40.92±9.64 42.11±0.11 0.560 Leukocytes (x 10°/L) 8.78±2.51 17.55±4.21 <0.001 Liver function AST (U/L) 51.97±17.24 50.68±17.32 0.719 test ALT (U/L) 52.57±24.18 59.86±26.5 0.163 Albumin (mg/dl) 28.54±7.34 28.59±6.92 0.971 Bilirubin (mg/dl) 0.33±0.1 0.35±0.1 0.286 Kidney Creatinine (mg/dl) 3.1±0.98 6.06±1.76 <0.001 function test Urea (mg/dl) 136.03±5.85 136.65±5.99 0.615 Serum Na(mEq/L) 4.02±0.48 2.33±0.28 <0.001 Serum Mg(mg/dL) 2.23±0.36 2.28±0.41 0.508	comorbidity	Hypothyroidism	1(1.59%)	2(5.41%)	0.553
Recurrent or acute admission RA 48(76.19%) 14(37.84%) AA 15(23.81%) 23(62.16%) <0.001*	·		19(30.16%)	2(5.41%)	0.004*
acute admission AA 15(23.81%) 23(62.16%) <0.001* Laboratory Parameters CBC Hematocrit (%) 40.92±9.64 42.11±0.11 0.560 Leukocytes (x 10°/L) 8.78±2.51 17.55±4.21 <0.001* Liver function test AST (U/L) 51.97±17.24 50.68±17.32 0.719 Bilirubin (mg/dl) 28.54±7.34 28.59±6.92 0.971 Bilirubin (mg/dl) 0.33±0.1 0.35±0.1 0.286 Kidney function test Creatinine (mg/dl) 3.1 ± 0.98 6.06±1.76 <0.001 Serum Na(mEq/L) 136.03±5.85 136.65±5.99 0.615 Serum Mg(mg/dL) 2.23±0.36 2.28±0.41 0.508		Renal	6(9.52%)	11(29.73%)	0.009*
admission AA 15(23.81%) 23(62.16%) Laboratory Parameters CBC Hematocrit (%) 40.92±9.64 42.11±0.11 0.560 Leukocytes (x 10 ⁹ /L) 8.78±2.51 17.55±4.21 <0.001 Liver function AST (U/L) 51.97±17.24 50.68±17.32 0.719 test ALT (U/L) 52.57±24.18 59.86±26.5 0.163 Albumin (mg/dl) 28.54±7.34 28.59±6.92 0.971 Bilirubin (mg/dl) 0.33±0.1 0.35±0.1 0.286 Kidney Creatinine (mg/dl) 3.1 ± 0.98 6.06±1.76 <0.001 function test Urea (mg/dl) 136.03±5.85 136.65±5.99 0.615 Serum Na(mEq/L) 136.03±5.85 136.65±5.99 0.615 Serum Mg(mg/dL) 2.23±0.36 2.28±0.41 0.508	Recurrent or	RA	48(76.19%)	14(37.84%)	
CBC Hematocrit (%) 40.92±9.64 42.11±0.11 0.560 Leukocytes (x 10 ⁹ /L) 8.78±2.51 17.55±4.21 <0.001 Liver function AST (U/L) 51.97±17.24 50.68±17.32 0.719 test ALT (U/L) 52.57±24.18 59.86±26.5 0.163 Bilirubin (mg/dl) 28.54±7.34 28.59±6.92 0.971 Bilirubin (mg/dl) 0.33±0.1 0.35±0.1 0.286 Kidney Creatinine (mg/dl) 3.1 ± 0.98 6.06±1.76 <0.001 function test Urea (mg/dl) 136.03±5.85 136.65±5.99 0.615 Serum Na(mEq/L) 4.02±0.48 2.33±0.28 <0.001 Serum Mg(mg/dL) 2.23±0.36 2.28±0.41 0.508	acute	AA	15(23.81%)	23(62.16%)	<0.001*
Liver function test Leukocytes (x 10 ⁹ /L) 8.78±2.51 17.55±4.21 <0.001 AST (U/L) 51.97±17.24 50.68±17.32 0.719 ALT (U/L) 52.57±24.18 59.86±26.5 0.163 Albumin (mg/dl) 28.54±7.34 28.59±6.92 0.971 Bilirubin (mg/dl) 0.33±0.1 0.35±0.1 0.286 Kidney Creatinine (mg/dl) 3.1±0.98 6.06±1.76 <0.001		La	boratory Parameters		
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	CBC	Hematocrit (%)	40.92±9.64	42.11±0.11	0.560
test ALT (U/L) 52.57±24.18 59.86±26.5 0.163 Albumin (mg/dl) 28.54±7.34 28.59±6.92 0.971 Bilirubin (mg/dl) 0.33±0.1 0.35±0.1 0.286 Kidney Creatinine (mg/dl) 3.1±0.98 6.06±1.76 <0.001		Leukocytes (x 10 ⁹ /L)	8.78±2.51	17.55 ± 4.21	<0.001*
Albumin (mg/dl) 28.54±7.34 28.59±6.92 0.971 Bilirubin (mg/dl) 0.33±0.1 0.35±0.1 0.286 Kidney Creatinine (mg/dl) 3.1±0.98 6.06±1.76 <0.001 function test Urea (mg/dl) 149.97±18.16 183.7±19.7 <0.001 Electrolytes Serum Na(mEq/L) 136.03±5.85 136.65±5.99 0.615 Serum K (mEq/L) 2.23±0.36 2.28±0.41 0.508	Liver function	AST (U/L)	51.97±17.24	50.68±17.32	0.719
Kidney Bilirubin (mg/dl) 0.33±0.1 0.35±0.1 0.286 Kidney Creatinine (mg/dl) 3.1±0.98 6.06±1.76 <0.001 function test Urea (mg/dl) 149.97±18.16 183.7±19.7 <0.001 Electrolytes Serum Na(mEq/L) 136.03±5.85 136.65±5.99 0.615 Serum K (mEq/L) 2.23±0.36 2.28±0.41 0.508	test	ALT (U/L)	52.57±24.18	59.86±26.5	0.163
Kidney Bilirubin (mg/dl) 0.33±0.1 0.35±0.1 0.286 Kidney Creatinine (mg/dl) 3.1±0.98 6.06±1.76 <0.001 function test Urea (mg/dl) 149.97±18.16 183.7±19.7 <0.001 Electrolytes Serum Na(mEq/L) 136.03±5.85 136.65±5.99 0.615 Serum K (mEq/L) 2.23±0.36 2.28±0.41 0.508		Albumin (mg/dl)	28.54±7.34	28.59±6.92	0.971
Kidney function test Creatinine (mg/dl) 3.1 ± 0.98 6.06 ± 1.76 <0.001 function test Urea (mg/dl) 149.97 ± 18.16 183.7 ± 19.7 <0.001			0.33±0.1	0.35±0.1	0.286
function test Electrolytes Urea (mg/dl) 149.97±18.16 183.7±19.7 <0.001 Serum Na(mEq/L) 136.03±5.85 136.65±5.99 0.615 Serum K (mEq/L) 4.02±0.48 2.33±0.28 <0.001	Kidney		3.1 ± 0.98	6.06±1.76	<0.001*
Electrolytes Serum Na(mEq/L) 136.03±5.85 136.65±5.99 0.615 Serum K (mEq/L) 4.02±0.48 2.33±0.28 <0.001 Serum Mg(mg/dL) 2.23±0.36 2.28±0.41 0.508	•		149.97±18.16	183.7±19.7	<0.001*
Serum K (mEq/L)4.02±0.482.33±0.28<0.001Serum Mg(mg/dL)2.23±0.362.28±0.410.508	Electrolytes			136.65±5.99	0.615
Serum Mg(mg/dL) 2.23±0.36 2.28±0.41 0.508	•		4.02 ± 0.48	2.33±0.28	<0.001*
					0.508
Serum Ca (mg/dL) 8.89 ± 0.9 8.56 ± 0.86 0.079		Serum Ca (mg/dL)	8.89 ± 0.9	8.56 ± 0.86	0.079

Table 1: Demographic data, vital signs, type of lung disease, associated comorbidity and recurrent or acute admission of the studied groups

Data are presented as mean \pm SD or frequency (%). * Significant p value <0.05. NIV: Non-invasive ventilation, BMI: Body mass index, HR: Heart rate, DBP: Diastolic blood pressure, SBP: Systolic blood pressure, COPD: Chronic Obstructive Pulmonary Disease, DM: diabetes mellitus, HTN: hypertension, AA: acute admission, RA: recurrent admission, CBC: complete blood count, AST: Aspartate aminotransferase, ALT: Alanine transaminase.

	Successful NIV (n=63)	Failed NIV (n=37)	Р
	рН		
At admission	7.2±0.03	7.2±0.03	0.355
6h	7.2 ± 0.04	7.21±0.03	0.312
12h	7.21±0.06	7.21±0.06	0.671
24h	7.22 ± 0.09	7.22 ± 0.09	0.963
48h	7.3±0.15	7.28±0.16	0.612
	PaCO ₂ (mmHg)		
At admission	56.29±12.77	77.57±8.83	<0.001*
6h	53.35±13.71	75.54 ± 9.77	<0.001*
12h	45.81±13.35	67.57 ± 9.86	<0.001*
24h	43.57±13.31	65.59±9.47	<0.001*
48h	39.14±17.29	59.51±19.84	<0.001*
	HCO_3 (mEq/L)		
At admission	19.89±5.82	21.14±6.17	0.569
6h	19.05±3	19.22±3.47	0.798
12h	19.35±3.32	19.22 ± 4.24	0.862
24h	19.46±3.66	19.59 ± 4.52	0.872
48h	18.08 ± 7.86	18.86±7.16	0.619

Table 2: ABG of the studied groups.

Data are presented as mean \pm SD. * Significant p value <0.05. NIV: Non-invasive ventilation, HCo₃: Bicarbonate, PaCo₂: Partial pressure of carbon dioxide.

Table 3: APACHE score, NIV mode of the studied groups

	,	6	1	
		Successful NIV (n=63)	Failed NIV (n=37)	Р
APACHE score		14(12-19.5)	30(28 - 32)	<0.001*
NIV mode	CPAP	18 (28.57%)	27 (69.23%)	-0.001*
	BiPAP	45 (71.43%)	12 (30.77%)	<0.001*
Determined as forements (M/) as median (IIOD) * Simifant as Develop (0.05 ADACHE: A set a short land and				

Data are presented as frequency (%) or median (IIQR). * Significant as P value ≤ 0.05 . APACHE: Acute physiology and chronic health evaluation, NIV: Non-invasive ventilation, CPAP: Continuous positive airway pressure, BiPAP: Bilevel positive airway pressure.

Table 4: Univariate and	multivariate re	egression to p	predict failed NIV

			Univariate			Multivariate	
		Odds ratio	95% CI	Р	Odds ratio	95% CI	Р
Sex		0.2963	0.1230 to0.7139	0.006*	0.2396	0.0341 to1.6846	0.151
Weight(kg	()	0.920	0.885-0.957	<0.001*	0.851	0.780-0.928	<0.001*
BMI (kg/n	$BMI (kg/m^2)$		0.739-0.901	<0.001*	0.823	0.744-0.909	<0.001*
Cardiac co	omorbidity	0.132	0.028-0.607	0.009*	0.09	0.016-0.492	0.005*
Renal comorbidity		4.019	1.341- 12045	0.01*	3.517	1.02-12.125	0.046*
Recurrent admission	or acute	4.728	1.913-1168	<0.001*	0.395	1.504-10.371	0.005*
Types of lung	COPD	31.00	10.079	<0.001*	147.63	19.473- 1119.23	<0.001*
disease	Pneumonia	8.571	3.232-22.72	<0.001*	13.99	4.159-47.05	<0.001*
	Obstructive Sleep Apnea	0.256	0.098-0.670	<0.001*	1.262	1.156-1.378	<0.001*
APACHE score		1.272	1.166-1.388	<0.001*	1.262	1.156-1.378	<0.001*
BiPAP		0.192	0.079-0.462	0.002*	0.213	0.063-0.720	0.01*

*Significant as P value≤0.05, CI: Confidence interval. COPD: Chronic obstructive pulmonary disease, SBP" Systolic blood pressure, DBP: Diastolic blood pressure, APACHE: Acute physiology and chronic health evaluation.

Discussion

Chen et al^[10] carried out a retrospective clinical study on 46-bed mixed ICU aged more than 18 years, having indications for NIV: ARF resulting from all kinds of diseases such as pneumonia, ARDS, COPD, and cardiogenic asthma. pulmonary oedema. They showed that failed patients were more associated with ideal body weight (IBW) than successful patients. Also, Liu et al^[11] who conducted a retrospective observational study at 29bed ICU patients who underwent cardiac developed surgery and ARF after extubation. They demonstrated that BMI was significantly higher in successful NIV group than in failed NIV group and they noted that sex was insignificantly different between both groups. The smaller sample size and older mean age (59.4 years) may explain this difference from our results.

In the current study, heart rate, systolic blood pressure and respiratory rate were significantly lower in successful NIV than in failed NIV. Diastolic blood pressure was significantly higher in successful NIV than in failed NIV, in agreement with our results, Wafy et al^[12] carried out a prospective observational study on 150 patients who had non-invasive ventilation. They showed that high heart rate at admission was associated with NIV failure.

This came in line with Chen et al^[10] who noted that NIV failure appeared to have higher heart rate at the first day of ICU admission and had higher heart rate during NIV treatment. Also, Pons-Òdena et al^[13] carried out a prospective cohort study included all ARF patients that received NIV in a 14-bed Paediatric ICU. They demonstrated that patients with higher heart rates were more prone to noninvasive support failure.

However, Al-Rajhi et al^[14] performed a retrospective cohort study on 163 consecutive patients with community acquired pneumonia requiring ventilator support. They found that mean arterial pressure was insignificantly different between successful NIV and failed NIV groups. The different age and sample size may explain this difference from our results.

Our results revealed that chronic obstructive pulmonary disease (COPD) and pneumonia were significantly lower in successful NIV group than in failed NIV group. Pulmonary edema was significantly higher in successful NIV group than in failed NIV group.

our results are supported by Liu et al^[11]who found that COPD and pneumonia were significantly lower in successful NIV group than in failed NIV group.

In disagreement with our results, Wafy et al^[12] reported that obstructive lung disease was significantly higher in successful NIV group than in failed NIV group. The different sample size, different age and respiratory failure type may explain this difference from our results, Furthermore, Al-Rajhi et al^[14] found that COPD was significantly higher in successful NIV group than in failed NIV group.

Regarding the present study, APACHE score was significantly lower in successful NIV compared to failed NIV. This came in line with Wafy et al ^[12] who demonstrated that patients with failed NIV had significantly higher APACHE-II score in comparison to those with successful NIV. Our results revealed that in univariate and multivariate regression, sex, weight, BMI, cardiac and renal comorbidity, acute admission, types of lung disease, APACHE and BiPAP, weight, BMI, cardiac and renal comorbidity, recurrent or acute admission, types of lung disease, APACHE and BiPAP were independent predictors of failed NIV (P <0.05) while sex wasn't.

Limitations

- It was a single center study
- Small sample size that may produce insignificant results
- Short follow up.

Conclusions:

Physicians must be alert when applying NIV for different types of respiratory failure patients and keep predictors of NIV failure (BMI, cardiac and renal comorbidity, recurrent or acute admission, types of lung disease, APPCHE and mode of NIV) into consideration for better outcome.

List of Abbreviations

LIST OF ADI	
NIV	Noninvasive Ventilation
ICU	Intensive Care Unit
RCU	Respiratory Center Unit
ARF	Acute Respiratory Failure
COPD	Chronic Obstructive Pulmonary
	Disease
ETI	Endotracheal Intubation
BMI	Body Mass Index
SOFA	Sequential Organ Failure
	Assessment
APACHE	Acute Physiology and Chronic
	Health Evaluation
BiPAP	Bilevel Positive Airway Pressure
CPAP	Continuous Positive Airway
	Pressure
AST	Aspartate Aminotransferase,
ALT	Alanine Transaminase
HR	Heart Rate
DBP	Diastolic Blood Pressure
SBP	Systolic Blood Pressure
DM	Diabetes Mellitus
HTN	Hypertension
AA	Acute Admission
RA	Recurrent Admission

References:

- 1. Brodie D, Slutsky AS, Combes A. Extracorporeal life support for adults with respiratory failure and related indications: A review. JAMA. 2019;322:557-68.
- 2. Rodríguez A, Ferri C, Martin-Loeches I, Díaz E, Masclans JR, Gordo F, et al. Risk factors for noninvasive ventilation failure in critically ill subjects with confirmed influenza infection. Respir Care. 2017;62:1307-15.

- Scala R, Pisani L. Noninvasive ventilation in acute respiratory failure: Which recipe for success? Eur Respir Rev. 2018;27:18-29.
- 4. Ahmed M, Bayoumi H, Mohamed S, Wafy S. Predictors of non-invasive ventilation failure in respiratory intensive care. ATS. 2018;2807-.
- 5. Ergan B, Nasiłowski J, Winck JC. How should we monitor patients with acute respiratory failure treated with noninvasive ventilation? Eur Respir Rev. 2018;27:190-210.
- Esquinas A, Schreiber A, Petit A, Groff P, Purro A, Ferrari R, et al. Intra-hospital transport of patients on non-invasive ventilation: review analysis and key practical recommendations by International NIV Committee. Eur J Anaesthesiol. 2017;19:88-97.
- Ergan B, Nasiłowski J, Winck JC. How should we monitor patients with acute respiratory failure treated with noninvasive ventilation? Eur Respir Rev. 2018;27:80-99.
- 8. De Jong A, Wrigge H, Hedenstierna G, Gattinoni L, Chiumello D, Frat JP, et al. How to ventilate obese patients in the ICU. Intensive Care Med. 2020;46:2423-35.
- Masa JF, Pépin JL, Borel JC, Mokhlesi B, Murphy PB, Sánchez-Quiroga M. Obesity hypoventilation syndrome. Eur Respir Rev. 2019;28:19-29.
- Chen Q, Liu M, Liu B, Li W, Gao D, Xie L, et al. Predictive factors for failure of noninvasive ventilation in adult intensive care unit: A retrospective clinical study. Can Respir J. 2020;2020:1324348.
- 11. Liu Y, An Z, Chen J, Liu Y, Tang Y, Han Q, et al. Risk factors for noninvasive ventilation failure in patients with post-extubation acute respiratory failure after cardiac surgery. J Thorac Dis. 2018;10:3319-28.
- 12. Wafy SM, Bayomy HA, Mohamed SA, Ahmed MK. Predictors of non-invasive ventilation failure in respiratory intensive care. Egypt J Crit Care Med. 2021;8:24-32.
- Pons-Òdena M, Medina A, Modesto V, Martín-Mateos MA, Tan W, Escuredo L, et al. [What are the most reliable predictive factors of non-invasive ventilation failure in paediatric intensive care units?]. An Pediatr (Engl Ed). 2019;91:307-16.
- 14. Al-Rajhi A, Murad A, Li PZ, Shahin J. Outcomes and predictors of failure of noninvasive ventilation in patients with community-acquired pneumonia in the ED. Am J Emerg Med. 2018;36:347-51.

To cite this article: Ahmed G. EL-Gazzar, Amany A. Abd Allah, Mohamed S. Ali, Rehab E. El-Sawy. Predictors of Noninvasive Ventilation Failure in Intensive Care Unit. BMFJ 2025;42(4):627-633